Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Significant Decline in Short Interest

Keros Therapeutics, Inc. (NASDAQ:KROS) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,720,000 shares, a decline of 9.9% from the September 30th total of 3,020,000 shares. Based on an average daily volume of 337,800 shares, the short-interest ratio is currently 8.1 days.

Keros Therapeutics Trading Down 2.7 %

KROS stock opened at $58.04 on Friday. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The business’s 50 day moving average is $55.95 and its 200-day moving average is $51.93. The firm has a market cap of $2.18 billion, a P/E ratio of -11.31 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the business earned ($1.27) EPS. Sell-side analysts forecast that Keros Therapeutics will post -4.88 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KROS. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Guggenheim initiated coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $89.11.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. boosted its position in Keros Therapeutics by 8.8% in the first quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock valued at $468,000 after buying an additional 574 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 1.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after acquiring an additional 251 shares in the last quarter. FORA Capital LLC acquired a new position in shares of Keros Therapeutics in the 1st quarter worth approximately $561,000. GSA Capital Partners LLP grew its position in Keros Therapeutics by 25.5% during the 1st quarter. GSA Capital Partners LLP now owns 8,538 shares of the company’s stock worth $565,000 after acquiring an additional 1,736 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Keros Therapeutics by 22.0% during the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after purchasing an additional 9,000 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.